Key things to know about how Elon Musk has boosted hard-right figures in Europe
Musk is a kingmaker on the platform he acquired in 2022 for $44 billion. He has used his influence to cultivate hard-right politicians and insurgent activists across Europe. A retweet or reply from Musk can lead to millions of views and tens of thousands of new followers, according to an Associated Press analysis of public data.
That fact has not been lost on influencers who have tagged Musk persistently, seeking a reply or a retweet. It has also fueled concerns in Europe about foreign meddling -- not from Russia or China, but from the United States.
'Every alarm bell needs to ring,' Christel Schaldemose, a vice president of the European Parliament who works on electoral interference and digital regulation, told AP.
The Associated Press analyzed more than 20,000 posts, which were compiled by Bright Data, over a three-year period from a sample of 11 European figures who had significant interactions with Musk and frequently promote a hard-right political or social agenda.
These case studies are not meant to be representative of a broad universe; rather they showcase the ways in which Musk's engagement can have an impact on local influencers that share his views.
Musk has sweeping power to direct attention on X
Since acquiring Twitter in October 2022, Elon Musk's followers have more than doubled, to over 220 million. No other large account has shown such high or consistent growth.
The result: If Musk's X account is his megaphone, it has gotten a lot bigger since he took over -- a change that has global implications.
The accounts Musk has been promoting are part of a growing global alliance of nationalistic parties and individuals united in common cause to halt migration, overturn progressive policies and promote an absolutist vision of free speech, which has rattled the foundation of a trans-Atlantic bond that guided U.S. and European relations for over eight decades.
Several of the accounts AP analyzed belong to people who have faced allegations of illegal behavior in their own countries. Tommy Robinson, an anti-immigrant agitator in the U.K., was sentenced in October to 18 months in prison for violating a court order blocking him from making libelous allegations against a Syrian refugee. Bjoern Hoecke, a politician from Germany's Alternative for Deutschland (AfD) party, was convicted last year of knowingly using a Nazi slogan in a speech.
Italian vice premier Matteo Salvini was acquitted in December of allegations he illegally detained 100 migrants aboard a humanitarian rescue ship
Among the others examined by AP: Alice Weidel, who helped lead Germany's Alternative for Deutschland (AfD) party to its best electoral showing this year; Eva Vlaardingerbroek, a Dutch influencer known as the 'shieldmaiden of the far-right'; Naomi Seibt, a German activist dubbed the 'anti-Greta Thunberg' now living in what amounts to political exile in Washington DC; Rubén Pulido and Foro Madrid, both associated with Spain's populist Vox party; and Fidias Panayioutou, a politician from Cyprus who has also advocated for Musk's companies.
These accounts collectively gained roughly 5 million followers from the time Musk took over Twitter in October 2022 through January of this year. Most saw triple-digit percentage increases in their followers -- as high as 920%, or in one case of a tiny account exploding over that time, topping 6,000%. Even some accounts that grew more steadily on their own saw their follower counts sharply begin rising once Musk started interacting with them. Similarly, on days Musk interacted with a post, the number of views the account got soared — in most cases, accruing two to four times as many views, with a few seeing boosts 30 or 40 times their normal daily viewership.
More established players in Musk's orbit -- like Italian Prime Minister Giorgia Meloni, whose ruling Brothers of Italy party has neo-fascist roots — benefit less when Musk interacts with them on X, AP found.
Attention seekers know that getting Musk to engage can be transformative
Musk's dominance creates a strong incentive for people to get Musk to engage with their content.
Naomi Seibt, a German climate skeptic, pinged Musk nearly 600 times over the past three years. Musk finally engaged in June 2024, when he asked her to explain why the Alternative for Germany (AfD) party is so controversial in Germany.
Since then, Musk has replied to, quoted or tagged Seibt more than 50 times, and her followers have grown by more than 320,000 since Musk took over the platform. On days Musk interacted with Seibt, her posts, on average, got 2.6 times as many views.
'I didn't intentionally 'invade' Elon's algorithm,' Seibt told AP. 'Obviously Elon has a lot of influence and can help share a message even with those who are usually glued to the legacy media, particularly in Germany.'
Musk's online influence has real-world political and financial impact
Alice Weidel, who helps lead the Alternative for Germany (AfD) party, saw her daily audience surge from 230,000 to 2.2 million on days Musk interacted with her posts on X. After Musk hosted a livestream with Weidel on X, vice president JD Vance broke protocol and met her in Munich. Weidel's party, which is fighting a lawsuit to block the German government's decision to designate it as an extremist group, went on to secure its best electoral showing ever.
Musk has also used X to advocate for the leader of Italy's hard-right League party, Matteo Salvini. On days Musk interacted with Salvini's account, average views were more than four times higher than usual. Now serving as vice premier, Salvini has urged his government to move ahead with controversial contracts for Starlink and pushed back against European efforts to regulate content on X.
And Musk has a friend in Brussels: Fidias Panayiotou — a 25-year-old social media influencer from Cyprus. Before winning a surprise seat in the European Parliament last year, the Cypriot spent weeks on a quest to get Elon Musk to hug him. In January 2023, his wish came true. Their embrace went viral. Since taking office, Panayiotou has praised X on the floor of the European Parliament, pushed back against regulations that impact the platform, and credited Musk with sparking his call to fire 80% of EU bureaucrats.
Musk, evidently, was pleased. 'Vote for Fidias,' he wrote on X. 'He is smart, super high energy and genuinely cares about you!'
The endorsement has been viewed 11.5 million times.
—-
Kessler reported from Washington
—-
Contact AP's global investigative team at Investigative@ap.org or https://www.ap.org/tips/
Erika Kinetz And Aaron Kessler, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Pfizer CEO details talks with Trump administration on tariffs, Most Favored Nations pricing
Pfizer (PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the COVID-19 pandemic when the two were in regular contact to help speed up vaccine production. That relationship, he said, has created a direct line to discuss some of the headwinds the company faces out of Washington, D.C. In his second term, Trump is targeting the drug industry for high prices and overseas production — threatening tariffs as high as 250% on imported drugs. But Bourla told Yahoo Finance he believes Trump and other officials in D.C. are having productive conversations with industry leaders about tariffs and drug pricing. "I think [Trump] is educated, of course he doesn't go into the details, it's not his job, but he understands the dynamics [of the industry]," Bourla said. When asked about the tariff threat, Bourla shared his understanding from his ongoing discussions. "I don't want to speak for the president, but what he said today, which was very important also, was that it would be a very small tariff in the first couple of years. And then he opened the window for a grace period. Because I had this discussion with him and I had this discussion with multiple other members of the administration," Bourla said. Read more: What Trump's tariffs mean for the economy and your wallet The industry is awaiting the results of an investigation by the administration into how those tariffs will be implemented — and Bourla said the devil will be in the details. Currently, more than 90% of prescriptions in the US are from generics, which are often the cheapest drug type. Branded drugs are often the most expensive and are largely produced in the US. But some early components of the manufacturing process, key chemicals known as active pharmaceutical ingredients (APIs), are often made overseas in Europe or Asia. That will be important to understand when the final ruling for the tariffs is made. "We need to understand if the API will dictate the country of origin, or where the final product is made," Bourla said. Pfizer is also one of the companies that received a letter from Trump last week detailing demands to reduce prices for Medicare and Medicaid enrollees to match the lowest price paid by developing nations, known as Most Favored Nations (MFN). The company is currently planning for the implementation of reduced prices, as well as working on how to mitigate negative impacts, Bourla said. "We are still discussing it with the president. ... The devil could be in the details in these stages," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Opera to Announce Second Quarter 2025 Financial Results on August 19, 2025
OSLO, Norway, Aug. 5, 2025 /PRNewswire/ -- Opera Limited (NASDAQ: OPRA), one of the world's major browser developers and a leading internet consumer brand, announced today that the company's second quarter 2025 financial results will be released before the market opens on Tuesday, August 19, 2025. The earnings release will be available on our investor relations website at Management will host a conference call to discuss the second quarter 2025 financial results on the same day at 8:00 a.m. ET. Listeners may access the call by dialing the following numbers: United States: +1 800-225-9448Norway: +47 80-01-3780International: +1 203-518-9708 Confirmation Code: OPRAQ225 A live webcast of the conference call can be accessed at About OperaOpera is a user-centric and innovative software company focused on enabling the best possible internet browsing experience across all devices. Hundreds of millions use the Opera web browsers for their unique and secure features on their mobile phones and desktop computers. Founded in 1995, and headquartered in Oslo, Norway, Opera is a public company listed on the Nasdaq stock exchange under the ticker symbol "OPRA". Download the Opera web browser and access other Opera products from Learn more about Opera at View original content to download multimedia: SOURCE Opera Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data